| Objective: To analyze the differences in coagulation parameters between patients with lung cancer,patients with benign lung diseases,and healthy controls.Explore thrombomodulin,thrombin-antithrombin III complex,and tissue plasminogen activator-Inhibitor 1 complex,plasmin-α2 plasmin inhibitor complex and conventional coagulation parameters(AT,PT,APTT,FIB,D-dimer,FDP)are available,The differential diagnosis of prethrombotic state in patients with lung cancer was analyzed.The changes of coagulation function in lung cancer patients with different pathological types,chemotherapy and non-chemotherapy,extrapulmonary metastasis and no extrapulmonary metastasis were analyzed and compared.Methods: 61 patients with primary lung cancer,61 patients with benign lung disease and 61 healthy controls were selected as lung cancer group,benign lung disease group and healthy control group.According to pathological types of lung cancer patients,they were divided into lung adenocarcinoma group,lung squamous cell carcinoma group,and small cell lung cancer group.According to the Khorana score,patients in the lung cancer group were divided into low-risk group,middle-risk group and high-risk group.First,compare the levels of TM,TAT,PIC,t-PAIC,AT,PT,APTT,FIB,D-dimer,and FDP between the lung cancer group,the benign lung disease group,and the healthy control group,and evaluate whether the above indicators can be used as Identify the indicators of prethrombotic state in lung cancer group and lung benign disease group.The above indicators were compared between the lung adenocarcinoma group,the lung squamous cell carcinoma group,and the small cell lung cancer group to evaluate whether the coagulation activity was different in different pathological types of lung cancer.The above indicators were compared between chemotherapy and non-chemotherapy,metastasis and non-metastasis in patients with lung cancer.The above indicators were placed in the low-risk group,middle-risk group,and high-risk group,which were divided by the Khorana score.Whether the above indicators could represent the risk of VTE in lung cancer patients was evaluated.Result: 1.There was a statistically significant difference in the levels of TM,TAT,PIC,t-PAIC,AT,APTT,FIB,D-dimer,and FDP between the lung cancer group(P<0.05),the benign lung disease group,and the healthy control group.Compared with the lung benign disease group,the levels of TM and TAT in the lung cancer group increased,and the APTT level decreased.There was a statistically significant difference(P<0.05).Compared with the healthy control group,the lung cancer group TM,TAT,PIC,t-PAIC,FIB,D-dimer and FDP levels increased,and AT levels decreased.There was a statistically significant difference(P<0.05).Compared with healthy controls,levels of t-PAIC,APTT,FIB,D-dimer,and FDP in the benign pulmonary disease group All increased,AT levels decreased,the difference was statistically significant(P<0.05).It indicates that patients with lung cancer may be in prethrombotic state.2.There were significant differences in the levels of TM,PIC,FIB,and TT between the lung adenocarcinoma,squamous cell carcinoma,and small cell lung cancer groups(P<0.05).Compared with the lung squamous cell carcinoma group,the level of TM and TT in the lung adenocarcinoma group decreased.There was a statistically significant difference(P<0.05).Compared with the small cell lung cancer group,the PIC level in the lung adenocarcinoma group increased,and the TT level decreased.Statistical significance(P<0.05);Compared with the small cell lung cancer group,the levels of TM,PIC,FIB,and TT in the lung squamous cell carcinoma group were increased,and the difference was statistically significant(P<0.05).This indicates that patients with non-small cell lung cancer are more likely to have thrombosis than patients with small cell lung cancer.3.Compared with lung cancer patients who have not received chemotherapy,the TAT levels of lung cancer patients who have undergone chemotherapy increase,and there is a statistically significant difference(P<0.05).This indicates that patients with lung cancer who have undergone chemotherapy are more likely to have thrombosis than those who have not received chemotherapy.4.Compared with lung cancer patients without extrapulmonary metastasis,the D-dimer and FDP levels of lung cancer patients with extrapulmonary metastasis were higher,and the difference was statistically significant(P<0.05).It has been shown that patients with lung cancer who have developed extrapulmonary metastases are more likely to have thrombosis than those who do not have extrapulmonary metastases.5.The patients in lung cancer group were firstly scored by Khorana prediction model,divided into middle-risk group and high-risk group,and then compared the various coagulation indexes of middle-risk group and high-risk group,and finally concluded that with the Khorana prediction model Compared with patients in the high-risk group,the levels of TM,TAT,FIB,D-dimer,and FDP in the intermediate-danger group had a statistically significant difference(P<0.05).These results indicate that these markers are consistent with the Khorana predictive model and can serve as a risk assessment indicator for VTE in lung cancer patients.Conclusion: The results of this study show that TM,TAT,and PIC levels may predict prethrombotic state in lung cancer patients;non-small cell lung cancer can be found based on TM,PIC,FIB,TT levels Compared with patients with small cell lung cancer,patients with thrombosis are more likely to have thrombosis.According to TAT levels,lung cancer patients receiving chemotherapy may be more likely to have non-chemotherapy lung cancer patients.Based on D-dimer and FDP levels,lung cancer patients with extra-pulmonary metastases can be found to be more likely to have thrombosis than lung cancer patients without extra-pulmonary metastases;Finally by comparing TM,TAT,and FIB in the Khorana prediction model.The levels of D-dimer and FDP indicated that they could be used as indicators to assess the risk of developing VTE in lung cancer patients. |
